Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.

Felix Gold Limited (ASX: FXG) Managing Director and CEO Anthony Reilly discusses the exploration success the team delivered in the short period since IPO, showing potential to host up to 3.6Moz in NW Array alone and the potential of Felix’ other prospects in this world-class mining region.

EBR Systems Inc (ASX: EBR) is the world’s only provider of wireless, endocardial (inside the heart) pacing systems in a US$2.5 billion addressable market.

Spectur (ASX: SP3) MD Gerard Dyson discusses how the company’s wide technological moat leaves the company with no direct competition, its weighted sales pipeline which has grown 94% year-on-year as at June 2022, and how Spectur are ready to scale and move into its next growth phase.

Far East Gold’s Chairman of the Board Paul Walker discusses the company’s six advanced porphyry-and epithermal-rich gold and copper projects across Indonesia and Australia, and its upcoming IPO opportunity.

Zoom2u Technologies is the parent company of same-day delivery platform Zoom2u and global last mile delivery SaaS platform Locate2u.

Great Boulder is a mineral exploration company with a portfolio of highly prospective gold and base metals assets ranging from greenfields to advanced exploration.

Pureprofile is a data and insights organisation and SaaS operator providing industry-leading online research solutions to agencies, marketers, researchers and brands.

Site Group International (ASX: SIT) International Operations Director Vernon Wills discusses how the company believes they are on the way to achieving circa $31 million revenue in FY25, and how they enable the likes of ExxonMobil, GE and OceanaGold to run successful and safe operations in developing parts of the world.

Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses how Prescient is advancing its deep pipeline, including moving OmniCAR towards clinical studies and progressing PTX-100 and PTX-200 further through the clinic. What the recent Q-Gen contract means for producing first OmniCAR T-cells for upcoming clinical trials, based on the encouraging progress of the AML program.

Graham Howard, Managing Director at VHM Limited, provides a high-level overview of the entire business and a pre-IPO opportunity to invest in a company that aims to build a globally significant rare earth mineral project.

Acrow Formwork and Construction Services Ltd (ASX: ACF) a leading provider of smart integrated construction systems responsible for the redevelopment of projects such as the MCG, the Brisbane Airport Link and AAMI Park, Melbourne.